Potent antimicrobial peptide against Gram-negative (P.aeruginosa, K.pneumoniae, E.coli, A.baumannii) (PubMed:25100358, PubMed:26465972). Shows moderate activities against Gram-positive bacteria (E.faecalis, S.aureus, S.pyogenes) (PubMed:25100358, PubMed:26465972). Also shows antifungal activity against standard and clinical isolates of yeasts (MIC=10-40 uM) and dermatophytes (MIC=1-5 uM) (PubMed:27876749). Adopts an amphipathic alpha helical conformation, that may allow to partition into the target membrane (PubMed:26465972). Shows high toxicity towards human fibroblasts (micromolar ranges) (PubMed:26465972). Shows low hemolytic activities on human erythrocytes (PubMed:25100358, PubMed:26465972). Also shows toxicity (micromolar ranges) when tested on many leukemia cell lines (PubMed:26465972). In addition, when tested in vitro on the parasite Trypanosoma cruzi (responsible of the Chagas disease), is able to reduce the number of the three forms (epimastigote, trypomastigote and amastigote) by inducing cell death through necrosis (PubMed:29208061). Forms a helical membrane channel in the prey (By similarity). Expressed by the venom gland. Promising drug candidate or lead for the development of new drugs to treat Chagas disease (also called American Trypanosomiasis). Shows a high selectivity index (SI) of 203.2 to the trypomastigote forms. The putative mature sequence has been predicted by AMPA, a predictive algorithm for identification of peptide stretches with antimicrobial properties. Belongs to the cathelicidin family.